Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1993-06-21
1995-08-29
Schwartz, Richard A.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
536 241, C12Q 168
Patent
active
054459419
ABSTRACT:
The present invention relates to methods for the identification of therapeutic agents for the treatment of osteoporosis and serum lipid lowering agents. The invention relates to isolating cloning, and using nucleic acids from the promoter regions of transforming growth factor .beta. genes comprising novel regulatory elements designated "raloxifene responsive elements". The invention also encompasses eukaryotic cells containing such raloxifene responsive elements operably linked to reporter genes such that the raloxifene responsive elements modulate the transcription of the reporter genes. The invention provides methods for identifying anti-osteoporosis agents that induce transcription of genes operably linked to such raloxifene responsive elements without inducing deleterious or undesirable side effects associated with current anti-osteoporosis therapy regimens.
REFERENCES:
patent: 4418068 (1983-11-01), Jones
patent: 5183736 (1993-02-01), Pfahl et al.
Lewin (1990) "Genes IV". pp. 65-69. Oxford University Press New York, N.Y.
Berry et al (1990) EMBO J. 9(9), 2811-2818.
Turner et al. (1988) Endocrinol. 122(3), 1146-1150.
Reese and Katzenellenbogen, 1991, Nucleic Acids Res. 19(23): 6595-6602, "Differential DNA--binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen receptor overexpressed in Mammaliam cells."
Colletta, et al., 1990, Br. J. Cancer 62: 405-409, "Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts."
Gaub, et al., 1990, Cell 63: 1267-1276, "Activation of the Ovalbumin Gene by the Estrogen Receptor Involves the Fos-Jun Complex."
Love et al., 1992, N. Eng. J. Med. 326: 852-6, "Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women With Breast Cancer."
Love et al., 1991, Annals of Int. Med. 115: 860-864, "Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women."
ten Dike et al., 1990 Molecular and Cell Biol. 10(9): 4473-4479, "Recombinant Transforming Growth Factor Type .beta.3: Biological Activities and Receptor-Binding Properties in Isolated Bone Cells."
Pellerin et al., 1992, Endocrinology 181: 1094-1100, "Superinduction of c-Fos Gene Expression by Estrogen in Cultured Guinea-Pig Endometrial Cells Requires Priming by a Cycloheximide-Dependent Mechanism."
Klinge et al., 1992, J. Steroid Biochem. Molec. Biol. 43(4): 249-262, "Antiestrogen-Liganded Estrogen Receptor Interaction with Estrogen Responsive element DNA In Vitro."
Chambon, P., 1984, Recent Prog. Horm. Res. 40: 1-42, "Promoter Elements of Genes Coding for Proteins Modulation of Transcription by Estrogens and Progesterone."
Kumar et al., 1986, EMBO J. 5(9): 2231-6, "Localization of the oestradiol-binding and putative DNA-binding domains of the human estrogen receptor."
Krust et al., 1986, EMBO J. 5(5): 891-7, "The Chicken oestrogen receptor sequence: homology with v-erbA and the human oestrogen and glucocorticoid receptors."
Kumar, 1988, Cell 55(1); 145-56, "The Estrogen Receptor Binds Tightly to Its Responsive Element as a Ligand-Induced Homodimer."
Murdoch and Gorski, 1991, Molecular and Cellular Endo. 78(1991): C103-C108, "At the Cutting Edge: The role of ligand in estrogen receptor regulation of gene expression."
Ringold, 1985, Ann. rev. Pharmacol. Toxicol. 25: 529-66, "Steriod Hormone Regulation of Gene Expression."
Evans, 1988, Science 249: 889-895, "The Steroid and Thyroid Hormone Receptor Superfamily."
King, 1987, J. Endocr. 114: 341-349, "Structure and function of steroid receptors."
Fuller, 1991, FASEB J. 5: 3092-3099, "The steroid receptor superfamily: mechanisms of diversity."
Finkelman et al., 1992, Proc. Natl. Acad Sci. USA 89(24): 12190-3, "Ovarienctomy selectively reduces the concentration of transforming growth factor .beta. in rate bone": Implications for estrogen deficiency-associated bone loss.
Flaumenhalft et al., 1993, J. Cell Biol. 120(4): 995-1002, "Role of the Latent TGF-.beta. Binding Protein in the Activation of Latent TGF-.beta. by Co-Cultures of Endothelial and Smooth Muscle Cells."
Butta et al., 1992, Cancer Res. 52(15): 4261-4, "Induction of Transforming Growth Factor .beta..sub.1 in Human Breast Cancer In Vivo following Tamoxifen Treatment."
Murphy et al., 1992, J. Steriod Biochem. Mol Biol. 41(3-8): 309-314, "Regulation of Transforming Growth Factor Gene Expression in Human Endometrial Adenocarcinoma Cells."
Gong et al., 1992, Cancer Res. 52(7): 1704-9, "Differential Effects of Estrogen and Aniestrogen on Transforming Growth Factor Gene Expression in Endometrial Adenocarcinoma Cells."
Saeki et al., 1991, Mol. Endocrinol. 5(12): 1955-63, "Regulation by Estrogen through the 5'-Flanking Region of the Transforming Growth Factor .alpha. Gene."
Knabbe et al., 1991, Am. J. Clin. Oncol. 14 Supp 2: 515-520, "Induction of Transforming Growth Factor .beta. by the Antiestrogens Droloxifene, Tamoxifen, and Toremifene in MCF-7 Cells."
Arrick et al., 1990, Cancer Res. 50(2): 299-303, "Differential Regulation of Expression of Three TransformingGrowth Factor .beta. Species in Human Breast Cancer Cell Lines by Estradiol."
Wakeling et al., 1989, J. Mol. Endocrinol. 2(3): 225-34, "Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells."
Noma Takafumi, 1991, Growth Factors, vol. 4, pp. 247-255, "Molecular Cloning and Structure of the Human Transforming Growth Factor-.beta. 2 Gene Promoter."
Mundy, Gregory R., The Effects of TGF-.beta. on Bone pp. 137-151.
Lafyratis, et al., The Journal of Biological Chemistry, vol. 265, No. 31, Issue of Nov. 5, pp. 19128-19136, "Structural and Functional Characterization of the Transforming Growth Factor .beta.3 Promoter."
Kim, Seong-Jin, The Jorunal of Biological Chemistry, vol. 265, No. 31, Issue of Nov. 5, pp. 19128-19136, "Characterization of the Promoter Region of the Human Transforming Growth Factor-.beta. Gene."
Sporn, Michael B., The Journal of Cell Biology, vol. 105, 1987, pp. 1039-1045, "Some Recent Advances in the Chemistry and Biology of Transforming Growth Factor-Beta."
Massaque, Joan, Cell, vol. 49, pp. 437-438, May 22, 1987, "The TGF--.beta. Family of Growth and Differentation Factors."
Moses, Harold L., Cell, vol. 63, pp. 245-247, Oct. 19, 1990, "TGF--.beta. Stimulation and Inhibition of Cell Proliferation: New Mechanistic Insights."
Boone David E.
Dahling Gerald V.
Eli Lilly and Company
Gurian-Sherman Douglas
Leeds James P.
LandOfFree
Method for screening anti-osteoporosis agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for screening anti-osteoporosis agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for screening anti-osteoporosis agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1818909